The life sciences industry is changing. Product lifecycles are decreasing, individual product revenues are shrinking and regulatory pressure is rising. According to the IMS Institute for Healthcare Informatics, generic drugs will account for 39 percent of market spending by 2015, up from 20 percent in 2005.
At the same time, the industry’s customers are evolving. Today, well-informed individuals, integrated provider networks, and government and other payers wield significant power over pricing. In the future, life sciences companies will increasingly turn to unfamiliar emerging global markets—each with their own regulations, cultural preferences, patient needs and public expectations.
The supply chain that many organizations have come to depend on is no longer effective.